FDA Conditionally Approves First Drug to Manage Acute Pancreatitis in Dogs

November 17, 2022 by Dan McCue
FDA Conditionally Approves First Drug to Manage Acute Pancreatitis in Dogs
(Photo by Anna Dudkova via UnSplash)

WASHINGTON — The Food and Drug Administration has conditionally approved Panoquell-CA1 for the management of clinical signs associated with acute onset of pancreatitis in dogs. 

Panoquell-CA1 is an injectable drug intended for use while the dog is hospitalized for treatment of the disease.  

Pancreatitis is a painful inflammatory disease of the pancreas that can be life-threatening and generally requires that dogs be hospitalized for treatment. In most cases, it occurs spontaneously. 

Common factors that increase the chance of developing pancreatitis include when dogs eat something outside of their normal diet (particularly fatty foods), treatment with certain medications, and diseases like diabetes mellitus, the FDA said.


It is more common in certain breeds of dogs and in some dogs may become a recurring or chronic condition. 

“This is the first drug to address a serious and life-threatening disease that previously could only be managed through supportive care, such as intravenous fluids, pain medication, antiemetics, and dietary rest,” said Steven M. Solomon, D.V.M., M.P.H., director of the FDA’s Center for Veterinary Medicine, in a written statement. 

“The conditional approval pathway allows medications like Panoquell-CA1 to reach the marketplace more quickly, and in this case gives dogs suffering from acute onset of pancreatitis earlier access to a drug to manage this disease,”  he said.

Conditional approval means that, when used according to the label, the drug is safe and has a reasonable expectation of effectiveness. 


The initial conditional approval is valid for one year with the potential for four annual renewals. 

During this time, the animal drug sponsor – in this case Ishihara Sangyo Kaisha Ltd. – must demonstrate active progress toward proving substantial evidence of effectiveness for full approval. 

If the sponsor does not meet the requirements for substantial evidence of effectiveness at the conclusion of five years, the product can no longer be marketed.

Fuzapladib sodium, the active ingredient in Panoquell, has been approved since 2018 in Japan to improve clinical signs in the acute phase of pancreatitis in dogs, but not in the United States until Tuesday. 

The FDA reviewed data associated with fuzapladib’s use in Japan as part of its assessment of the application for conditional approval. 

The agency said veterinarians should advise owners about the possible side effects, which include loss of appetite, digestive tract disorders, respiratory tract disorders, liver disease and jaundice, before using the drug. 


It is also encouraging dog owners to work with their veterinarian to report any adverse events or side effects potentially related to the use of any drug, including Panoquell-CA1. 

Dan can be reached at [email protected] and at https://twitter.com/DanMcCue

A+
a-

In The News

Health

Voting

Regulation

November 17, 2022
by Dan McCue
FDA Conditionally Approves First Drug to Manage Acute Pancreatitis in Dogs

WASHINGTON — The Food and Drug Administration has conditionally approved Panoquell-CA1 for the management of clinical signs associated with acute... Read More

WASHINGTON — The Food and Drug Administration has conditionally approved Panoquell-CA1 for the management of clinical signs associated with acute onset of pancreatitis in dogs.  Panoquell-CA1 is an injectable drug intended for use while the dog is hospitalized for treatment of the disease.   Pancreatitis is a... Read More

November 14, 2022
by Dan McCue
NRC Publishes Annual Report to Congress on Nuke Security Inspections

WASHINGTON — The Nuclear Regulatory Commission has released an unclassified version of its annual report to Congress detailing the prior... Read More

WASHINGTON — The Nuclear Regulatory Commission has released an unclassified version of its annual report to Congress detailing the prior year’s security inspection program.  The report, required under the Energy Policy Act of 2005, provides information to Congress and the public regarding the overall security and... Read More

November 14, 2022
by Dan McCue
Governments Urged to Regulate Supply Chains as Demand for Critical Minerals Grows

PARIS — As the world continues to transition toward net-zero emissions, the rising demand for renewable energy is expected to... Read More

PARIS — As the world continues to transition toward net-zero emissions, the rising demand for renewable energy is expected to continue to increase demand for critical minerals.  To ensure they continue to have a safe, secure and sustainable supply, a new report from the International Energy... Read More

November 10, 2022
by Dan McCue
FTC Taking Dim View of Musk Action Amid Twitter Turmoil

WASHINGTON — A letter posted to Twitter’s Slack feed by a company lawyer, detailing the utter chaos the social media... Read More

WASHINGTON — A letter posted to Twitter’s Slack feed by a company lawyer, detailing the utter chaos the social media outlet has descended into since Elon Musk took control of it, has prompted a rare public rebuke from the Federal Trade Commission. “We are tracking recent... Read More

November 8, 2022
by Tom Ramstack
Supreme Court Hints at New Limits on Authority of Federal Agencies

WASHINGTON — U.S. Supreme Court justices implied Monday they are likely to make it easier to challenge the authority of... Read More

WASHINGTON — U.S. Supreme Court justices implied Monday they are likely to make it easier to challenge the authority of regulatory agencies in disputes with the Securities and Exchange Commission and the Federal Trade Commission. The key issue in Axon Enterprise v. Federal Trade Commission was... Read More

November 8, 2022
by Dan McCue
Health Care Issues on the Ballot in Several States

WASHINGTON — It’s not just the control of the U.S. House and Senate that’s hanging in the balance as voters... Read More

WASHINGTON — It’s not just the control of the U.S. House and Senate that’s hanging in the balance as voters go to the polls today, in states across the nation ballots are being cast on health care issues ranging from abortion to Medicaid expansion and the... Read More

News From The Well
scroll top